The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation

M Zonneveld; HJ Flink; E Verheij-Hart; H Senturk; S Zeuzem; US Akarca; Y Cakaloglu; C Simon; TMK So; G Gerken; Rob de Man; Bettina Hansen; Solko Schalm; HLA Janssen

doi:10.1111/j.1365-2036.2005.02453.x

The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation

M Zonneveld, HJ Flink, E Verheij-Hart, H Senturk, S Zeuzem, US Akarca, Y Cakaloglu, C Simon, TMK So, G Gerken, Rob de Man, Bettina Hansen, Solko Schalm, HLA Janssen

Gastroenterology & Hepatology

Research output: Contribution to journal › Article › Academic › peer-review

72 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	1163-1171
Number of pages	9
Journal	Alimentary Pharmacology & Therapeutics
Volume	21
Issue number	9
DOIs	https://doi.org/10.1111/j.1365-2036.2005.02453.x
Publication status	Published - 2005

Research programs

EMC MM-04-20-02-A
EMC NIHES-01-64-03

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1111/j.1365-2036.2005.02453.x

http://hdl.handle.net/1765/56848

Cite this

Zonneveld, M., Flink, HJ., Verheij-Hart, E., Senturk, H., Zeuzem, S., Akarca, US., Cakaloglu, Y., Simon, C., So, TMK., Gerken, G., de Man, R., Hansen, B., Schalm, S., & Janssen, HLA. (2005). The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation. Alimentary Pharmacology & Therapeutics, 21(9), 1163-1171. https://doi.org/10.1111/j.1365-2036.2005.02453.x

@article{e199935dd0924d479f7b6f355a6d9c2e,

title = "The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation",

author = "M Zonneveld and HJ Flink and E Verheij-Hart and H Senturk and S Zeuzem and US Akarca and Y Cakaloglu and C Simon and TMK So and G Gerken and {de Man}, Rob and Bettina Hansen and Solko Schalm and HLA Janssen",

year = "2005",

doi = "10.1111/j.1365-2036.2005.02453.x",

language = "Undefined/Unknown",

volume = "21",

pages = "1163--1171",

journal = "Alimentary Pharmacology & Therapeutics",

issn = "0269-2813",

publisher = "John Wiley & Sons Inc.",

number = "9",

}

Zonneveld, M, Flink, HJ, Verheij-Hart, E, Senturk, H, Zeuzem, S, Akarca, US, Cakaloglu, Y, Simon, C, So, TMK, Gerken, G, de Man, R, Hansen, B, Schalm, S & Janssen, HLA 2005, 'The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation', Alimentary Pharmacology & Therapeutics, vol. 21, no. 9, pp. 1163-1171. https://doi.org/10.1111/j.1365-2036.2005.02453.x

TY - JOUR

T1 - The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: predictive factors for dose reduction and treatment discontinuation

AU - Zonneveld, M

AU - Flink, HJ

AU - Verheij-Hart, E

AU - Senturk, H

AU - Zeuzem, S

AU - Akarca, US

AU - Cakaloglu, Y

AU - Simon, C

AU - So, TMK

AU - Gerken, G

AU - de Man, Rob

AU - Hansen, Bettina

AU - Schalm, Solko

AU - Janssen, HLA

PY - 2005

Y1 - 2005

U2 - 10.1111/j.1365-2036.2005.02453.x

DO - 10.1111/j.1365-2036.2005.02453.x

M3 - Article

C2 - 15854180

SN - 0269-2813

VL - 21

SP - 1163

EP - 1171

JO - Alimentary Pharmacology & Therapeutics

JF - Alimentary Pharmacology & Therapeutics

IS - 9

ER -